To assess whether the expression of MSR1 or CD86 would predict survival after transplantation in IPF patients, ROC curve analysis was used to evaluate the discriminating capability of the two biomarkers to differentiate IPF patients from PAH subjects. This evidence concerns the gene MSR1 and pulmonary arterial hypertension.